Grifols is a global healthcare company headquartered in Barcelona, Spain. The company produces and markets plasma-derived medicines as well as hospital pharmacy products, compounded IV solutions, and in vitro diagnostic products for clinical laboratories. Grifols employs more than 8,000 people in the U.S. and 11,200 people worldwide, and its products are sold in more than 90 countries.
At A Glance
2410 Lillyvale Ave.
Bioscience: Specializes in the research, development, production and commercialization of high-quality plasma therapies.
At Grifols, a history of innovation defines our modern-day approach to medicine. More than 70 years ago, a Spanish hematologist named Dr. Jose Antonio Grifols Roig pursued a line of research that would set the stage for contemporary use of human plasma to treat disease. Together with his sons, he founded Laboratorios Grifols in 1940.
Among their pioneering achievements, they obtained a patent in Spain for the process of plasma lyophilization, or freeze-drying of human plasma, along with the devices needed to inject plasma into patients who required its therapeutic properties. Shortly thereafter, in 1951, Dr. Jose Antonio Grifols Lucas published the first large-scale clinical data describing the plasmapheresis technique of extracting plasma from donors while returning their red blood cells. Combined with the work of Edwin Cohn, Grifols paved the way for the birth of the plasma fractionation industry as we know it today.
From these auspicious beginnings, Grifols has evolved into an industry leader in the collection, manufacture and marketing of plasma-derived therapies. Through recent acquisitions, Grifols is now the third largest global producer of plasma-derived medicines. Grifols operates the world’s largest plasma collection platform, with 150 source plasma donation centers across the U.S.
Grifols currently has the world’s highest plasma protein fractionation capacity of more than 8 million liters of plasma per year. To accommodate the growing global demand for plasma-derived medicines, Grifols is significantly expanding its three manufacturing sites in Clayton, NC, Los Angeles, CA, and Barcelona, Spain—the company’s global headquarters. The expansions include a new, 185,000-square-foot fractionation facility in Clayton and a new facility in Los Angeles dedicated to the production of immune globulin therapies. The new manufacturing facilities will increase the company’s capacity to fractionate plasma to 12 million liters by 2015.
Edwin J. Cohn & Jose Antonio Grifols at the 4th International Congress of Blood Transfusion, Lisbon 1951.
In addition, this year, Grifols opened a new, state-of-the-art plasma testing laboratory in San Marcos, TX, where every plasma donation undergoes rigorous scientific analysis prior to being approved for use in manufacturing. The 72,000-square-foot-facility houses the latest technology for conducting sophisticated viral testing, including transcription mediated amplification to rapidly detect minute levels of viral material within plasma samples. The San Marcos laboratory, together with an existing plasma testing laboratory in Austin, will analyze millions of plasma samples annually.
Grifols is firmly committed to giving patients and healthcare providers broad access to our products. As Grifols grows, it continues to pursue its mission of improving the health and well-being of people around the world.
Flebogamma® DIF manufacturing plant in Barcelona, Spain, designed by Grifols Engineering.
This corporate profile was reviewed and approved by Grifols.